HTL’097 / Nxera Pharma - LARVOL DELTA

Identification and characterisation of a novel GLP-1 receptor antagonist peptide HTL0033097 (ACS-Sp 2022) - "In vivo administration of HTL0033097 reversed GLP-1 agonist stimulated insulin secretion and increased plasma glucose in both rodents and non-human primates consistent with the proposed mechanism of action. Based on these encouraging data HTL0033097 has progressed into pre-clinical development where it was shown to be well tolerated in rodent and non-rodent dose range finding safety studies.Disclosure of the chemical structure of HTL0033097, a summary of the design process and the supporting pre-clinical pharmacokinetic and pharmacodynamic profile will be presented."

Alzheimer's Disease • CNS Disorders • Cognitive Disorders • Epilepsy • Hypoglycemia • Rare Diseases • Vascular Neurology

Identification and characterisation of a dual GLP-1/GLP-2 agonist peptide, HTL0030023 using structure based drug design (ACS-Sp 2022) - "A novel peptide agonist with pharmacological activity at GLP-1 and GLP-2 receptors was designed to explore the hypothesis that peptides with dual pharmacology provide benefits on nutrient absorption and intestinal function. When compared to teduglutide, HTL0030023 promotes superior intestinal growth and additionally displays robust efficacy in the oral glucose tolerance assay, highlighting opportunity for differentiation from GLP-2 selective analogues.Based on the unique pharmacological profile, the molecule was further progressed into two further in vivo models to explore its therapeutic potential in metabolic diseases. HTL0030023 demonstrated encouraging efficacy in a mouse model of non-alcoholic steatohepatitis (NASH), as well as diet induced obesity (DIO), highlighting promising opportunities across multiple indications including non-alcoholic fatty liver disease (NAFLD) and NASH.HTL0030023 has completed rodent and non-rodent dose range finding (DRF) safety studies..."

Gastrointestinal Disorder • Genetic Disorders • Hepatology • Metabolic Disorders • Non-alcoholic Fatty Liver Disease • Non-alcoholic Steatohepatitis • Obesity • Short Bowel Syndrome

Newly added product: GLP-1 antagonist program (Heptares Press Release)

Pipeline update • Diabetes • Metabolic Disorders • Severe Hypoglycemia